Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study

ARTAÇ, MEHMET; Turha, Nazim; Kocer, Murat; KARABULUT, BÜLENT; Bozcuk, Hakan; Yalcin, Suayip; KARAAĞAÇ, MUSTAFA; Gunduz, Seyda; Isik, Nalan; Uygunl, Kazinn

doi:10.1700/1491.16397

Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study

ARTAÇ M., Turha N. S., Kocer M., KARABULUT B., Bozcuk H., Yalcin S., ...Daha Fazla

TUMORI J, cilt.100, sa.2, ss.143-148, 2014 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 100 Sayı: 2
Basım Tarihi: 2014
Doi Numarası: 10.1700/1491.16397
Dergi Adı: TUMORI J
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.143-148
Süleyman Demirel Üniversitesi Adresli: Evet

Özet

Background. A high-risk group of patients with stage II colon cancer has been identified by the results of studies in Western populations. The aim of this study was to investigate the prognostic factors of adjuvant chemotherapy in Turkish patients with stage II colon cancer.